D.C. Diagnosis Nicholas Florko What does the Build Back Better Act actually mean for the health care industry?
D.C. Diagnosis Nicholas Florko Which drug maker spent the most on lobbying this summer? The answer will surprise you
Politics Rachel Cohrs STAT Plus: There’s no point person in Biden’s HHS for its $187 billion Covid-19 fund for health care providers
STAT+ Conversations Rick Berke, Erin Mershon and Lev Facher STAT Plus: STAT+ Conversations: How pharma is influencing the 2020 election
D.C. Diagnosis Nicholas Florko and Lev Facher It’s a big week for debates about drug prices, whether pharma likes it or not
D.C. Diagnosis Nicholas Florko How pharma could benefit from one of Congress’ signature drug pricing ideas
D.C. Diagnosis Nicholas Florko STAT Plus: Is pharma’s R&D spending a mark of shame or a point of pride?
D.C. Diagnosis Nicholas Florko Will the Speaker’s office finally spill the beans on its drug pricing plan?